Literature DB >> 8461628

Cellular signaling by cyclosporine A in contractile cells: interactions with atrial natriuretic peptide.

H Meyer-Lehnert1, D Bokemeyer, U Friedrichs, S Drechsler, H J Kramer.   

Abstract

Immunosuppressive therapy with cyclosporine A (CyA) may be associated with severe side effects such as nephrotoxicity and arterial hypertension. The partial reversibility of these effects suggests that they are at least in part functional. The present study examined the effects of CyA on cellular signaling in vascular smooth muscle cells and in glomerular mesangial cells and the interactions with the endogenous vasodilator atrial natriuretic peptide (ANP). Intracellular free calcium concentrations ([Ca2+]i) were measured using Fura-2. 45Ca2+ was used to measure Ca2+ efflux and cellular Ca2+ influx. In the presence of cyclosporine (10 micrograms/ml), the Ca(2+)-mobilizing effects of angiotensin II (10(-8)M) in smooth muscle cells and of arginine vasopressin (AVP) in mesangial cells were significantly enhanced. CyA significantly stimulated cellular Ca2+ uptake in both cell types. ANP blocked the Ca2+ mobilization by angiotensin II and AVP and also completely inhibited the potentiating effect of CyA on angiotensin II- and AVP-induced Ca2+ mobilization. ANP also completely blocked the CyA-stimulated Ca2+ uptake. These findings suggest that CyA stimulates transmembrane Ca2+ influx, thereby increasing vasopressor-sensitive intracellular Ca2+ stores and augmenting vasopressor-induced Ca2+ mobilization. This cellular effect of CyA in vitro was markedly diminished by ANP. The effects of CyA on intracellular signaling may directly enhance the contractile response of smooth muscle and the glomerular mesangium to vasopressor stimuli and may also contribute to other disturbances of cell metabolism associated with CyA.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8461628     DOI: 10.1007/bf00179998

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  47 in total

1.  What is cyclosporine nephrotoxicity?

Authors:  B D Myers
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

2.  Effect of nifedipine on cyclosporine A-induced nephrotoxicity, urinary endothelin excretion and renal endothelin receptor number.

Authors:  D P Brooks; E H Ohlstein; L C Contino; B Storer; M Pullen; M Caltabiano; P Nambi
Journal:  Eur J Pharmacol       Date:  1991-02-26       Impact factor: 4.432

Review 3.  Cardiac transplant hypertension.

Authors:  R C Starling; R J Cody
Journal:  Am J Cardiol       Date:  1990-01-01       Impact factor: 2.778

4.  Cyclosporine, sympathetic activity, and hypertension.

Authors:  A L Mark
Journal:  N Engl J Med       Date:  1990-09-13       Impact factor: 91.245

5.  Effect of cyclosporine A on post-ischemic acute renal failure in conscious dogs: role of vasoactive renal hormones.

Authors:  H H Neumayer; M J Mihatsch; A Löpping; M Velten; K Wagner
Journal:  Transplant Proc       Date:  1988-06       Impact factor: 1.066

6.  Comparison of vascular smooth muscle cells from adult human, monkey and rabbit in primary culture and in subculture.

Authors:  J H Chamley; G R Campbell; J D McConnell; U Gröschel-Stewart
Journal:  Cell Tissue Res       Date:  1977-02-14       Impact factor: 5.249

7.  Cyclosporin A inhibits PGE2 release from vascular smooth muscle cells.

Authors:  A Kurtz; J Pfeilschifter; K Kühn; K M Koch
Journal:  Biochem Biophys Res Commun       Date:  1987-09-15       Impact factor: 3.575

Review 8.  The pathophysiology of Sandimmune (cyclosporine) in man and animals.

Authors:  J Mason
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

9.  Calcium homeostasis in intact lymphocytes: cytoplasmic free calcium monitored with a new, intracellularly trapped fluorescent indicator.

Authors:  R Y Tsien; T Pozzan; T J Rink
Journal:  J Cell Biol       Date:  1982-08       Impact factor: 10.539

10.  Diminished acetylcholine-induced vasodilation in renal microvessels of cyclosporine-treated rats.

Authors:  T Takenaka; Y Hashimoto; M Epstein
Journal:  J Am Soc Nephrol       Date:  1992-07       Impact factor: 10.121

View more
  2 in total

1.  Angiotensin II formation in the intact human heart. Predominance of the angiotensin-converting enzyme pathway.

Authors:  L S Zisman; W T Abraham; G E Meixell; B N Vamvakias; R A Quaife; B D Lowes; R L Roden; S J Peacock; B M Groves; M V Raynolds
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

Review 2.  Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19?

Authors:  Christian A Devaux; Cléa Melenotte; Marie-Dominique Piercecchi-Marti; Clémence Delteil; Didier Raoult
Journal:  Front Med (Lausanne)       Date:  2021-09-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.